Clinical trials: Colon Cancer Adenocarcinoma
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC)
THE-0504 in Patients With Solid Tumors
Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.
- Conditions
- Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer
- Trial name
- NCT07646106
- Testing
- THE-0504
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Thena Biotech S.r.l.
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
Advanced Solid Tumors Cancer
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics…
- Trial name
- NCT03821935
- Testing
- Livmoniplimab, Budigalimab
- Where
- 64 sites in United States, Australia and 12 more
- Volunteers
- 364 people
- Sponsor
- AbbVie
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02839954
- Testing
- anti-MUC1 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT06040541
- Testing
- RMC-9805, RMC-6236
- Where
- 17 sites in United States
- Volunteers
- 604 people
- Sponsor
- Revolution Medicines, Inc.
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Gastrointestinal Cancers, Cholangiocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- 18F-FAPI-74 GI (NCT05641896)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- SOFIE
Colorectal Cancer, Colorectal Polyp
Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical…
- Conditions
- Colorectal Cancer, Colorectal Polyp, Colorectal Adenoma, Colorectal Adenomatous Polyp
- Trial name
- NCT05988645
- Testing
- MiWEndo System
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- MiWEndo Solutions S.L.
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Cancer Metastatic to the Liver, Hepatocellular Carcinoma
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not…
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma
- Trial name
- NCT00986661
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Cancer, Non-small-cell Lung Cancer
Study of XL281 in Adults With Solid Tumors
The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer…
- Conditions
- Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer
- Trial name
- NCT00451880
- Testing
- XL281, famotidine
- Where
- 6 sites in United States
- Volunteers
- 180 people
- Sponsor
- Exelixis
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in…
- Trial name
- NCT07094113
- Testing
- AMG 410, Pembrolizumab, Panitumumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Breast Cancer, Non-Small Cell Lung Cancer
131-I-TM-601 Study in Adults With Solid Tumors
This study is designed to evaluate the ability of intravenously (IV)administered 131-I-labeled TM-601 (chlorotoxin) to provide tumor-specific localization(via radiographic imaging) in patients with recurrent or refractory primary…
- Conditions
- Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer
- Trial name
- NCT00379132
- Testing
- 131-I-TM-601 (chlorotoxin)
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- TransMolecular
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations.
- Trial name
- AURORAS-1 (NCT06983743)
- Testing
- ERAS-0015, ERAS-0015 in combination
- Where
- 9 sites in United States
- Volunteers
- 600 people
- Sponsor
- Erasca, Inc.